Clinical trials for therapeutic areas aside from COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world.
The biopharmaceutical sector faces disruption to clinical trials at all phases as the coronavirus pandemic continues. Also, some industry players are shifting R&D priorities toward finding new vaccines and treatments for COVID-19, potentially at the expense of other indications.
However, the industry is compelled to maintain its momentum in R&D in order to bring safe and effective therapies to...
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
